Chicago, IL (PRWEB) March 03, 2014 -- The birth control safety center at DrugNews.net is announcing updated information on the site for patients who used the contraceptives Yaz or Yasmin. A new report indicates approximately 8,250 claims alleging the drugs caused blood clot injuries have been settled*.
DrugNews is a free resource for patients taking popular prescription drugs. With information on the latest product recalls, safety alerts, research and litigation news, visitors can recognize potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
The birth control center has added health warnings from experts such as the FDA** and British Medical Journal*** that oral contraceptives like Yaz and Yasmin that contain the hormone drospirenone can increase the risk of blood clots.
Last month, the U.K.’s Medicines and Healthcare Products Regulatory Agency warned that certain birth control pills like Yasmin could double the risk of blood clots****.
Due to the number of patients who’ve filed a Yaz lawsuit alleging side effects in the United States, cases have been consolidated in a special federal court (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).
Now, DrugNews has learned Bayer has already spent $1.69 billion to settle around 8,250 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT), and will continue to evaluate new cases for settlement*.
Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to visit DrugNews or speak with a lawyer about their legal options.
Due to the specialized nature of these cases, DrugNews only recommends lawyers who have settled hundreds of Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugNews.net.
*Bayer Annual Report, Notes to Consolidated Financial Statement, Legal Risks, 2/28/14; annualreport2013.bayer.com/en/legal-risks.aspx
**FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
***BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
****British Journal of Family Medicine, Feb 2014; bjfm.co.uk/content/article.aspx?id=25769806997
Chris Schroeder, DrugNews, http://www.DrugNews.net, +1 888-987-4866, [email protected]
Share this article